These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35815468)

  • 1. Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate.
    Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz RJ; Reirden D; Malhotra M; Glenny C; Harding P; Powell T; Anderson PL; Hosek S
    AIDS Res Hum Retroviruses; 2022 Dec; 38(12):939-943. PubMed ID: 35815468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones.
    Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz R; Reirden D; Glenny C; Malhotra M; Anderson PL; Hosek S
    AIDS Res Hum Retroviruses; 2022 Nov; 38(11):840-846. PubMed ID: 35943868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
    Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
    J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
    Cirrincione LR; Podany AT; Havens JP; Bares SH; Dyavar SR; Gwon Y; Johnson TM; Amoura NJ; Fletcher CV; Scarsi KK
    J Antimicrob Chemother; 2020 May; 75(5):1242-1249. PubMed ID: 32065631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.
    Yager JL; Anderson PL
    Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):463-474. PubMed ID: 32250177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No observed bidirectional effect between tenofovir diphosphate concentrations and gender-affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis.
    Patel N; Morris S; Burke L; Chow K; Pacheco D; Anderson P; Stancyzk F; Blumenthal J
    Br J Clin Pharmacol; 2024 Oct; 90(10):2360-2365. PubMed ID: 38646796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis.
    Cattani VB; Jalil EM; Eksterman L; Torres T; Cardoso SW; Castro CRV; Monteiro L; Wilson E; Bushman L; Anderson P; Veloso VG; Grinsztejn B; Estrela R;
    J Antimicrob Chemother; 2022 Sep; 77(10):2729-2736. PubMed ID: 35815666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
    Grant RM; Pellegrini M; Defechereux PA; Anderson PL; Yu M; Glidden DV; O'Neal J; Yager J; Bhasin S; Sevelius J; Deutsch MB
    Clin Infect Dis; 2021 Oct; 73(7):e2117-e2123. PubMed ID: 32766890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
    Marzinke MA; Hanscom B; Wang Z; Safren SA; Psaros C; Donnell D; Richardson PA; Sullivan P; Eshleman SH; Jennings A; Feliciano KG; Jalil E; Coutinho C; Cardozo N; Maia B; Khan T; Singh Y; Middelkoop K; Franks J; Valencia J; Sanchez N; Lucas J; Rooney JF; Rinehart AR; Ford S; Adeyeye A; Cohen MS; McCauley M; Landovitz RJ; Grinsztejn B;
    Lancet HIV; 2023 Nov; 10(11):e703-e712. PubMed ID: 37783219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.
    Petruccelli KCS; Baía-da-Silva DC; Val F; Valões MS; Cubas-Vega N; Silva-Neto AV; Sampaio V; Alencar A; Pecoits-Filho R; Moreira RC; Cardoso SW; Moreira RI; Leite IC; Madruga JV; Kallas EG; Alencastro PR; Hoagland B; Grinsztejn B; Santos VGV; Lacerda MVG
    AIDS Res Ther; 2022 Feb; 19(1):12. PubMed ID: 35209929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study.
    Hiransuthikul A; Janamnuaysook R; Himmad K; Kerr SJ; Thammajaruk N; Pankam T; Phanjaroen K; Mills S; Vannakit R; Phanuphak P; Phanuphak N;
    J Int AIDS Soc; 2019 Jul; 22(7):e25338. PubMed ID: 31298497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
    Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
    J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.
    Cespedes MS; Das M; Yager J; Prins M; Krznaric I; de Jong J; Xiao D; Shao Y; Wong P; Kintu A; Carter C; Hoornenborg E; Ruane P; Phoenix J; Younis I; Halperin J
    Transgend Health; 2024 Feb; 9(1):46-52. PubMed ID: 38312459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-drug interactions between gender-affirming hormone therapy and antiretrovirals for treatment/prevention of HIV.
    Senneker T
    Br J Clin Pharmacol; 2024 Oct; 90(10):2366-2382. PubMed ID: 38866600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
    Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
    Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
    Liegeon G; Antoni G; Pialoux G; Capitant C; Cotte L; Charreau I; Tremblay C; Cua E; Senneville E; Raffi F; Meyer L; Molina JM;
    J Int AIDS Soc; 2020 Feb; 23(2):e25420. PubMed ID: 32086878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.
    Wohl DA; Spinner CD; Flamm J; Hare CB; Doblecki-Lewis S; Ruane PJ; Molina JM; Mills A; Brinson C; Ramgopal M; Clarke A; Crofoot G; Martorell C; Carter C; Cox S; Hojilla JC; Shao Y; Das M; Kintu A; Baeten JM; Grant RM; Mounzer K; Mayer K
    Lancet HIV; 2024 Aug; 11(8):e508-e521. PubMed ID: 39008999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
    Tang EC; Vittinghoff E; Anderson PL; Cohen SE; Doblecki-Lewis S; Bacon O; Coleman ME; Buchbinder SP; Chege W; Kolber MA; Elion R; Shlipak M; Liu AY
    J Acquir Immune Defic Syndr; 2018 Feb; 77(2):193-198. PubMed ID: 28991887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women.
    Tanaudommongkon A; Chaturvedula A; Hendrix CW; Fuchs EJ; Shieh E; Bakshi RP; Marzinke MA
    Br J Clin Pharmacol; 2022 Aug; 88(8):3674-3682. PubMed ID: 35285974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.